Androgen metabolism and JAK/STAT pathway genes and prostate cancer risk

Cancer Epidemiology

Volumn 36, Issue 4, 2012, Pages 347-353

  Kwon, Erika M ^a,b   Holt, Sarah K ^c   Fu, Rong ^c   Kolb, Suzanne ^c   Williams, Gabrielle ^a   Stanford, Janet L ^c,d   Ostrander, Elaine A ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Androgen pathway; Genetic susceptibility; HSD17B3; JAK2; Polymorphisms; Prostate cancer

Indexed keywords

AKR1C3 PROTEIN; ANDROGEN; ANDROGEN RECEPTOR; CYP17A1 PROTEIN; CYTOCHROME P450 17; HSD17B3 PROTEIN; HYDROXYSTEROID; JANUS KINASE 2; KALLIKREIN; KALLIKREIN 3; NCOA4 PROTEIN; NKX3.1 PROTEIN; STAT3 PROTEIN; SULT2A1 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANDROGEN METABOLISM; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AFRICAN AMERICANS; AGED; ANDROGENS; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84863436368     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2012.04.002     Document Type: Article

References (50)

1. Seigel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29.
2. Kim S.T., Cheng Y., Hsu F.C., Jin T., Kader A.K., Zheng S.L., et al. Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic variation. Prostate 2010, 70(16):1729-1738.
3. Huggins C., Hodges D.V. Studies on prosatate cancer: effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1:293-297.
4. Morgentaler A. Guilt by association: a historical perspective on Huggins, testosterone therapy, and prostate cancer. J Sex Med 2008, 5(8):1834-1840.
5. Ross R.K., Pike M.C., Coetzee G.A., Reichardt J.K., Yu M.C., Feigelson H., et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 1998, 58(20):4497-4504.
6. Wang Q., Li W., Zhang Y., Yuan X., Xu K., Yu J., et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009, 138(2):245-256.
7. Lu Y., Sun J., Kader A.K., Kim S.T., Kim J.W., Liu W. et al. Association of prostate cancer risk with snps in regions containing androgen receptor binding sites captured by ChIP-on-chip analyses. Prostate 2011.
8. Stanford J.L., Wicklund K.G., McKnight B., Daling J.R., Brawer M.K. Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999, 8(10):881-886.
9. Agalliu I., Salinas C.A., Hansten P.D., Ostrander E.A., Stanford J.L. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 2008, 168(3):250-260.
10. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21(2):263-265.
11. Hardy G.H. Mendelian proportions in a mixed population. Science 1908, 28(706):49-50.
12. Breslow N.E., Day N.E. Statistical methods in cancer research. Volume I - the analysis of case-control studies. IARC Sci Publ 1980, (32):5-338.
13. Gabriel S.B., Schaffner S.F., Nguyen H., Moore J.M., Roy J., Blumenstiel B., et al. The structure of haplotype blocks in the human genome. Science 2002, 296(5576):2225-2229.
14. Zhao L.P., Li S.S., Khalid N. A method for the assessment of disease associations with single-nucleotide polymorphism haplotypes and environmental variables in case-control studies. Am J Hum Genet 2003, 72(5):1231-1250.
15. Gauvreau K. Hypothesis testing: proportions. Circulation 2006, 114(14):1545-1548.
16. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007, 81(3):559-575.
17. Pollard M., Luckert P.H., Schmidt M.A. Induction of prostate adenocarcinomas in Lobund Wistar rats by testosterone. Prostate 1982, 3(6):563-568.
18. Andriole G.L., Bostwick D.G., Brawley O.W., Gomella L.G., Marberger M., Montorsi F., et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010, 362(13):1192-1202.
19. Hsing A.W., Chu L.W., Stanczyk F.Z. Androgen and prostate cancer: is the hypothesis dead?. Cancer Epidemiol Biomarkers Prev 2008, 17(10):2525-2530.
20. Yeager M., Orr N., Hayes R.B., Jacobs K.B., Kraft P., Wacholder S., et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007, 39(5):645-649.
21. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352(17):1779-1790.
22. Gu L., Zhu X.H., Visakorpi T., Alanen K., Mirtti T., Edmonston T.B., et al. Activating mutation (V617F) in the tyrosine kinase JAK2 is absent in locally-confined or castration-resistant prostate cancer. Anal Cell Pathol (Amst) 2010, 33(2):55-59.
23. Constantinescu S.N., Girardot M., Pecquet C. Mining for JAK-STAT mutations in cancer. Trends Biochem Sci 2008, 33(3):122-131.
24. Barton B.E., Karras J.G., Murphy T.F., Barton A., Huang H.F. Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther 2004, 3(1):11-20.
25. De Miguel F., Lee S.O., Onate S.A., Gao A.C. Stat3 enhances transactivation of steroid hormone receptors. Nucl Recept 2003, 1(1):3.
26. Agarwal C., Tyagi A., Kaur M., Agarwal R. Silibinin inhibits constitutive activation of Stat3: and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis 2007, 28(7):1463-1470.
27. Kwon E.M., Salinas C.A., Kolb S., Fu R., Feng Z., Stanford J.L., et al. Genetic polymorphisms in inflammation pathway genes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2011, 20(5):923-933.
28. Mononen N., Schleutker J. Polymorphisms in genes involved in androgen pathways as risk factors for prostate cancer. J Urol 2009, 181(4):1541-1549.
29. Lindström S., Zheng S.L., Wiklund F., Jonsson B.A., Adami H.O., Bälter K.A., et al. Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway. Prostate 2006, 66(16):1729-1743.
30. Severi G., Hayes V.M., Tesoriero A.A., Southey M.C., Hoang H.N., Padilla E.J., et al. The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels. BJU Int 2008, 101(4):492-496.
31. Lindstrom S., Zheng S.L., Wiklund F., Jonsson B.A., Adami H.O., Balter K.A., et al. Systematic replication study of reported genetic associations in prostate cancer: strong support for genetic variation in the androgen pathway. Prostate 2006, 66(16):1729-1743.
32. Margiotti K., Kim E., Pearce C.L., Spera E., Novelli G., Reichardt J.K. Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men. Prostate 2002, 53(1):65-68.
33. Beuten J., Gelfond J.A., Franke J.L., Weldon K.S., Crandall A.C., Johnson-Pais T.L., et al. Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2009, 18(6):1869-1880.
34. Cunningham J.M., Hebbring S.J., McDonnell S.K., Cicek M.S., Christensen G.B., Wang L., et al. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev 2007, 16(5):969-978.
35. Wilborn T.W., Lang N.P., Smith M., Meleth S., Falany C.N. Association of SULT2A1 allelic variants with plasma adrenal androgens and prostate cancer in African American men. J Steroid Biochem Mol Biol 2006, 99(4-5):209-214.
36. Eeles R.A., Kote-Jarai Z., Giles G.G., Olama A.A., Guy M., Jugurnauth S.K., et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008, 40(3):316-321.
37. Cicek M.S., Liu X., Casey G., Witte J.S. Role of androgen metabolism genes CYP1B1: PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev 2005, 14(9):2173-2177.
38. Mononen N., Seppälä E.H., Duggal P., Autio V., Ikonen T., Ellonen P., et al. Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res 2006, 66(2):743-747.
39. Pal P., Xi H., Sun G., Kaushal R., Meeks J.J., Thaxton C.S., et al. Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European origin. Hum Genet 2007, 122(3-4):251-259.
40. Riegman P.H., Vlietstra R.J., van der Korput J.A., Brinkmann A.O., Trapman J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 1991, 5(12):1921-1930.
41. Wang Q., Carroll J.S., Brown M. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell 2005, 19(5):631-642.
42. Ahn J., Berndt S.I., Wacholder S., Kraft P., Kibel A.S., Yeager M., et al. Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet 2008, 40(9):1032-1034. author reply 1035-36.
43. Kote-Jarai Z., Amin Al Olama A., Leongamornlert D., Tymrakiewicz M., Saunders E., Guy M., et al. Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum Genet 2011, 129(6):687-694.
44. He W.W., Sciavolino P.J., Wing J., Augustus M., Hudson P., Meissner P.S., et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 1997, 43(1):69-77.
45. Akamatsu S., Takata R., Ashikawa K., Hosono N., Kamatani N., Fujioka T., et al. A functional variant in NKX3.1 associated with prostate cancer susceptibility down-regulates NKX3.1 expression. Hum Mol Genet 2010, 19(21):4265-4272.
46. Thomas M.A., Preece D.M., Bentel J.M. Androgen regulation of the prostatic tumour suppressor NKX3.1 is mediated by its 3' untranslated region. Biochem J 2010, 425(3):575-583.
47. Kote-Jarai Z., Easton D.F., Stanford J.L., Ostrander E.A., Schleutker J., Ingles S.A., et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL consortium. Cancer Epidemiol Biomarkers Prev 2008, 17(8):2052-2061.
48. Wang Y., Ray A.M., Johnson E.K., Zuhlke K.A., Cooney K.A., Lange E.M. Evidence for an association between prostate cancer and chromosome 8q24 and 10q11 genetic variants in African American men: the Flint Men's Health Study. Prostate 2011, 71(3):225-231.
49. Pomerantz M.M., Shrestha Y., Flavin R.J., Regan M.M., Penney K.L., Mucci L.A. et al. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet 2010, 6(11):e1001204.
50. Chang B.L., Cramer S.D., Wiklund F., Isaacs S.D., Stevens V.L., Sun J., et al. Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Hum Mol Genet 2009, 18(7):1368-1375.